California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• California State Teachers Retirement System increased its Amneal Pharmaceuticals stake by 37.6%, purchasing 56,588 shares to hold 207,239 shares valued at approximately $2.58 million. Institutional investors and hedge funds collectively own 31.82% of the company.
• Amneal shares opened at $17.88 after declining 1.4%, with the stock trading between $8.50 and $19.26 over the past year. The company has a $5.70 billion market capitalization and a P/E ratio of 36.49.
• Analysts remain broadly positive, with seven Buy ratings and one Hold rating. The average price target is $17.67, while recent targets include $21 from Goldman Sachs and $25 from UBS.

California State Teachers Retirement System raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 37.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 207,239 shares of the company's stock after purchasing an additional 56,588 shares during the quarter. California State Teachers Retirement System owned 0.06% of Amneal Pharmaceuticals worth $2,576,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in Amneal Pharmaceuticals by 33.7% in the 1st quarter. Royal Bank of Canada now owns 12,646 shares of the company's stock valued at $157,000 after buying an additional 3,191 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Amneal Pharmaceuticals by 10.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 88,007 shares of the company's stock valued at $1,094,000 after acquiring an additional 8,347 shares during the period. Quantinno Capital Management LP increased its position in Amneal Pharmaceuticals by 38.5% in the 1st quarter. Quantinno Capital Management LP now owns 37,599 shares of the company's stock valued at $467,000 after acquiring an additional 10,457 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Amneal Pharmaceuticals by 93.3% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 254,373 shares of the company's stock valued at $3,162,000 after acquiring an additional 122,773 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Amneal Pharmaceuticals by 1,586.8% during the first quarter. Renaissance Technologies LLC now owns 276,637 shares of the company's stock valued at $3,439,000 after acquiring an additional 260,237 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Trading Down 1.4%

Shares of AMRX stock opened at $17.88 on Tuesday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $8.50 and a fifty-two week high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a 50 day simple moving average of $16.89 and a two-hundred day simple moving average of $14.48. The company has a market cap of $5.70 billion, a P/E ratio of 36.49 and a beta of 1.27.

Analysts Set New Price Targets

Several research analysts have commented on AMRX shares. Barclays lifted their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 20th. UBS Group raised their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. Weiss Ratings upgraded Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, July 29th. Finally, The Goldman Sachs Group reissued a "buy" rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $17.67.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source